Metraipolis › archive › dc_760ae5d03fae
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab — Europe PMC PMID:41298527
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41298527
- DOI
- 10.1038/s41523-[numero omesso]-4
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T06:03:30.522Z
- SHA-256 of the archived text
50563ecce29327be99d22e61a509834f0c66bedb0453d342c558fe48c0beb895- Stable URL of this page
https://metraipolis.com/documento/dc_760ae5d03fae
How to cite
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab — Europe PMC PMID:41298527 — Europe PMC (en), https://europepmc.org/article/MED/41298527 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_760ae5d03fae (Metraipolis archive dc_760ae5d03fae, sha256 50563ecce29327be99d22e61a509834f0c66bedb0453d342c558fe48c0beb895)
BibTeX
@misc{dc760ae5d03fae,
title = {Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab — Europe PMC PMID:41298527},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41298527},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_760ae5d03fae; sha256 50563ecce29327be99d22e61a509834f0c66bedb0453d342c558fe48c0beb895},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41298527. Agents can read the archived copy with the MCP tool read_document.